Conference Coverage Begins Aug 29, 2019
Conference Coverage Coming Soon…
Transcript: 852 – SpaceOAR® Hydrogel Application Video – Marcio Fagundes
Marcio Fagundes: Today, I’ll demonstrate the technique to inject SpaceOAR® hydrogel between the prostate and the rectum via transparent needle approach. SpaceOAR® displaces the rectum away from the prostate and further reduces the dose of radiation to the rectum, minimizing risks of side effects. As I will demonstrate, the procedure can be easily done in […]
Transcript: 985 – SpaceOAR® Hydrogel Procedure Demonstration – Juan Montoya
Juan Montoya: Hello, I’m Dr. Juan Montoya. I’m a urologist and the President of the Urology Center of Colorado. In this video, I will demonstrate the application technique for SpaceOAR® Hydrogel. SpaceOAR® Hydrogel is a temporary spacer that separates the prostate from the rectum. With this separation, the volume of normal tissue exposed to the […]
Mortality Associated with Statins in Men with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy – Beyond the Abstract
Statin use was found to be associated with delayed disease progression and reduced mortality in prostate cancer. Despite the mechanism by which statins possibly preventing cancer progression not yet being completely understood, the beneficial effects associated with statins and their relatively safe profile make them good candidates for additional therapy to standard treatment for prostate […]
Development and Validation of an Improved Pathological Nodal Staging System for Urothelial Carcinoma of the Bladder.
Current pathological nodal staging for bladder cancer is based on lymph node (LN) location but not on the number of positive LNs. We sought to improve prognostic classification by creating a novel staging system incorporating positive LN burden. We sampled 12515 patients with muscle-invasive bladder cancer (MIBC) from the National Cancer Database (NCDB) and 5928 […]
Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.
Neoadjuvant chemotherapy is underutilized in bladder cancer patients who undergo radical cystectomy. However, the quality of regimens used in this setting remains largely unknown. To determine utilization treatment patterns and survival outcomes according to regimens administered. We used the Surveillance, Epidemiology and End Results (SEER)-Medicare linked database to identify patients diagnosed with clinical stage TII-IV […]
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.
Patients with residual muscle-invasive urinary tract cancer after neoadjuvant chemotherapy (NAC) have a high risk of recurrence. To retrospectively evaluate whether additional adjuvant chemotherapy (AC) improves outcomes compared with surveillance in patients with significant residual disease despite NAC. We identified 474 patients who received NAC from the Retrospective International Study of Cancers of the Urothelium […]
Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study.
The objective of the study was to validate the characteristics of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model in patients treated with first-line axitinib in clinical practice. We retrospectively evaluated 143 patients with metastatic renal-cell carcinoma who were treated with axitinib as the first-line therapy between October 2008 and February 2019. Overall […]
How Does Treatment Uncertainty Factor into Decisions to Place Patients on Active Surveillance for Kidney Cancer?
There are various management options for localized kidney cancer, including active surveillance, thermal ablation, partial nephrectomy, and radical nephrectomy. Choosing the optimal management requires consideration of oncologic outcomes, overall survival, and potential harms associated with each option. Oncologic outcomes and overall survival are determined by tumor and patient characteristics, respectively, and represent relatively objective metrics. […]
Nonsurgical Salvage Local Therapies for Radiorecurrent Prostate Cancer: A Systematic Review and Meta-analysis.
Different nonsurgical therapeutic strategies can be adopted for intraprostatic relapse of prostate cancer after primary radiotherapy, including re-irradiation (with brachytherapy [BT] or external beam radiotherapy [EBRT]), high-intensity focused ultrasound (HIFU), and cryotherapy. The main issues to consider when choosing nonsurgical salvage local therapies are local tumor control and significant genitourinary toxicity. To conduct a systematic […]